Gérard Zalcman
Université Claude Bernard Lyon 1(FR)Centre National de la Recherche Scientifique(FR)Inserm(FR)Inserm(FR)Université Paris Cité(FR)Université Paris Sciences et Lettres(FR)University of California San Diego(US)Assistance Publique – Hôpitaux de Paris(FR)Assistance Publique – Hôpitaux de Paris(FR)Hôpital Bichat-Claude-Bernard(FR)Institut Curie(FR)Institut Curie(FR)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Occupational and environmental lung diseases, Lung Cancer Diagnosis and Treatment, Pleural and Pulmonary Diseases, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors(2017)5,249 cited
- → Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial(2015)1,421 cited
- → Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry(2019)1,334 cited
- → First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial(2021)1,154 cited
- → Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)(2016)972 cited
- →